ahead by-a-mil strong market
core growth stellar margin ep beat
sale yoy fx vs our/street estimate
core growth vs estimate guid street
gm adj opm yoy yoy
est respect higher volum help drive margin non-gaap ep
vs our/street est overal broad beat metric
biz perform well led strength pharma
chemic saw growth consecut quarter
pharma shrug revenu recognit issu core growth
academ government anoth strong quarter solid demand europ
china food dx clinic environment forens
key pharma end-market combin sale management note
broad-bas strength saw increas capital-expenditure explor refin
chemic custom strong market combin share gain due new product
offer pharma balanc instrument servic consum
small molecul biopharma market reaffirm underli demand strength
hearti guid rais upsid like
rais core revenu growth guid adj ep
mdpt guid core growth inclus
hit order time pull forward addit chines new
year well tough comp overal continu execut well
end-market strong year believ signific
upsid guidanc beyond core basi new product cycl gc
link link lc/m link capit deploy major beneficiari us tax
reform cash trap ou indic appetit
larger ie deal would support long-term growth see
opportun share buyback well remain lst focu stock
rais est reiter buy rais po
rais sale est ep rais po
base ebitda estimate given portfolio divers solid
fundament new product capit deploy oppi core growth peer
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart santa clara california agil
technolog lead supplier analyt
instrument consum product
use mainli research qualiti assur
applic custom life scienc
chemic analysi industri compani
known leader life scienc
industri long histori innov
well posit benefit
secular posit growth trend life
scienc chemic analysi food
environment test acquisit also
provid new opportun growth
under-penetrated market agil reduc
cyclic exposur restructur
spin electron test measur
busi keysight help unlock sharehold
valu increas strateg flexibl
po base ev/ebitda multipl modest premium
median valuat agil life scienc peer group
believ justifi given agil margin expans potenti upsid new gc
product cycl macro improv solid organ revenu growth outlook strateg
option opportun capit deploy execut
risk po econom risk fx risk slower expect uptak new
product expans new market competit risk reduct spend
integr risk takeout specul overhang
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
